Neumora Therapeutics, Inc.(NMRA)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

NMRA Neumora Therapeutics, Inc.

休市中 02-06 16:00:00 EST

2.12

+0.16

+8.16%

盘后2.11

-0.01-0.47%

19:12 EST

最高2.16	最低1.98	成交量111.53万
今开2.02	昨收1.96	日振幅9.18%
总市值3.60亿	流通市值1.82亿	总股本1.70亿
成交额234.47万	换手率1.30%	流通股本8,606万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"NMRA","market":"US","secType":"STK","nameCN":"Neumora Therapeutics, Inc.","latestPrice":2.12,"timestamp":1770411600000,"preClose":1.96,"halted":0,"volume":1115258,"hourTrading":{"tag":"盘后","latestPrice":2.11,"preClose":2.12,"latestTime":"19:12 EST","volume":1851,"amount":3913.09,"timestamp":1770423179340,"change":-0.01,"changeRate":-0.004717,"amplitude":0.014151},"delay":0,"changeRate":0.08163265306122457,"floatShares":86062982,"shares":170000000,"eps":-1.463171,"marketStatus":"休市中","change":0.16,"latestTime":"02-06 16:00:00 EST","open":2.02,"high":2.16,"low":1.98,"amount":2344706.8205168,"amplitude":0.091837,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.463171,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1770627600000},"marketStatusCode":7,"adr":0,"listingDate":1694750400000,"exchange":"NASDAQ","adjPreClose":1.96,"preHourTrading":{"tag":"盘前","latestPrice":2.02,"preClose":1.96,"latestTime":"09:25 EST","volume":1160,"amount":2286.9345479999997,"timestamp":1770387900017,"change":0.06,"changeRate":0.030612,"amplitude":0.035714},"postHourTrading":{"tag":"盘后","latestPrice":2.11,"preClose":2.12,"latestTime":"19:12 EST","volume":1851,"amount":3913.09,"timestamp":1770423179340,"change":-0.01,"changeRate":-0.004717,"amplitude":0.014151},"volumeRatio":1.8173593484997215,"impliedVol":1.4545,"impliedVolPercentile":0.6454},"requestUrl":"/m/hq/s/NMRA","defaultTab":"news","newsList":[{"id":"2604917764","title":"Neumora Therapeutics, Inc.盘中异动 临近收盘股价大跌5.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2604917764","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604917764?lang=zh_cn&edition=full","pubTime":"2026-01-17 04:56","pubTimestamp":1768596970,"startTime":"0","endTime":"0","summary":"北京时间2026年01月17日04时56分，Neumora Therapeutics, Inc.股票出现波动，股价急速下跌5.16%。Neumora Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.14%。Neumora Therapeutics, Inc.公司简介：Neumora Therapeutics Inc 是一家临床阶段的生物制药公司，成立的初衷是通过采用一种全新的方法来开发脑部疾病治疗方案，以应对脑部疾病危机。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026011704561097a2270f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026011704561097a2270f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","BK4539","NMRA","LENZ","BK4139"],"gpt_icon":0},{"id":"1189252236","title":"Neumora Therapeutics阿尔茨海默症早期研究结果积极 股价应声上涨10%","url":"https://stock-news.laohu8.com/highlight/detail?id=1189252236","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1189252236?lang=zh_cn&edition=full","pubTime":"2026-01-05 22:32","pubTimestamp":1767623547,"startTime":"0","endTime":"0","summary":"Neumora Therapeutics公司公布其早期阿尔茨海默病研究的积极结果后，市场反应热烈，该公司股价大幅攀升10%。\n这项突破性进展为治疗这种神经退行性疾病带来了新的希望，显著提振了投资者信心。研究数据展示了公司在神经科学领域的研发实力，预示着其候选药物具备良好的开发前景。\n股价的强劲表现反映了市场对Neumora Therapeutics创新管线的认可，也凸显了生物技术板块对重大临床进展的高度敏感性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NMRA"],"gpt_icon":0},{"id":"1151848712","title":"Neumora Therapeutics公布2026年管线战略与关键里程碑展望","url":"https://stock-news.laohu8.com/highlight/detail?id=1151848712","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1151848712?lang=zh_cn&edition=full","pubTime":"2026-01-05 19:37","pubTimestamp":1767613067,"startTime":"0","endTime":"0","summary":"Neumora Therapeutics, Inc.今日宣布其关键管线进展与2026年预期里程碑，这些成果将支撑公司通过新一代创新疗法重塑神经科学药物开发的使命，为脑疾病患者提升治疗结果与生活质量。Neumora宣布计划在每项KOASTAL研究中增加招募人数，在原始目标332例基础上最高提升25%。Neumora Therapeutics, Inc.是一家临床阶段生物制药公司，致力于通过革新脑疾病治疗开发模式应对全球脑疾病危机。除法律要求外，Neumora无义务更新或修订前瞻性陈述。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PAM","BK4132","AD","BK4563","NMRA","BK4081","BK4007"],"gpt_icon":0},{"id":"1131995877","title":"Neumora Therapeutics公布NMRA-511治疗阿尔茨海默病激越症状的1B期信号探索研究积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1131995877","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1131995877?lang=zh_cn&edition=full","pubTime":"2026-01-05 19:32","pubTimestamp":1767612720,"startTime":"0","endTime":"0","summary":"Neumora Therapeutics公司近日宣布，其针对阿尔茨海默病激越症状研发的药物NMRA-511，在1B期信号探索研究中取得了积极成果。这项研究旨在评估NMRA-511的安全性、耐受性及初步疗效信号，结果显示该药物在主要终点和关键次要终点上均表现出显著改善。数据表明NMRA-511有望为阿尔茨海默病相关的激越症状提供新的治疗选择，公司计划基于这些结果推进后续临床开发。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NMRA"],"gpt_icon":0},{"id":"1176825221","title":"Neumora Therapeutics Inc - 从与K2 Healthventures的现有风险债务工具中提取额外4000万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1176825221","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1176825221?lang=zh_cn&edition=full","pubTime":"2025-11-06 20:30","pubTimestamp":1762432229,"startTime":"0","endTime":"0","summary":"Neumora Therapeutics Inc - 从与K2 Healthventures的现有风险债务工具中提取额外4000万美元","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NMRA"],"gpt_icon":0},{"id":"1117668391","title":"Neumora Therapeutics Inc - 预计将在年底前公布Nmra-511在阿尔茨海默病激动症的1B期研究数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1117668391","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1117668391?lang=zh_cn&edition=full","pubTime":"2025-11-06 20:26","pubTimestamp":1762431980,"startTime":"0","endTime":"0","summary":"Neumora Therapeutics Inc - 预计将在年底前公布Nmra-511在阿尔茨海默病激动症的1B期研究数据","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NMRA","BK4007"],"gpt_icon":0},{"id":"1151793252","title":"Neumora Therapeutics Inc - 预计截至2025年9月30日的现金、现金等价物及可出售证券，将支持其运营计划至2027年","url":"https://stock-news.laohu8.com/highlight/detail?id=1151793252","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1151793252?lang=zh_cn&edition=full","pubTime":"2025-11-06 20:25","pubTimestamp":1762431911,"startTime":"0","endTime":"0","summary":"Neumora Therapeutics Inc - 预计截至2025年9月30日的现金、现金等价物及可出售证券，将支持其运营计划至2027年","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NMRA","BK4007"],"gpt_icon":0},{"id":"1192571705","title":"Neumora Therapeutics启动M4阳性变构调节剂Nmra-898的第一阶段临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1192571705","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1192571705?lang=zh_cn&edition=full","pubTime":"2025-10-27 19:02","pubTimestamp":1761562939,"startTime":"0","endTime":"0","summary":"Neumora Therapeutics启动M4阳性变构调节剂Nmra-898的第一阶段临床研究","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NMRA","BK4007"],"gpt_icon":0},{"id":"1136301010","title":"Neumora Therapeutics在饮食诱发肥胖的临床前模型中展示了NMRA-215的领先减重效果","url":"https://stock-news.laohu8.com/highlight/detail?id=1136301010","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136301010?lang=zh_cn&edition=full","pubTime":"2025-10-27 18:30","pubTimestamp":1761561026,"startTime":"0","endTime":"0","summary":"Neumora Therapeutics在饮食诱发肥胖的临床前模型中展示了NMRA-215的领先减重效果","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NMRA","BK4007"],"gpt_icon":0},{"id":"2553426987","title":"瑞穗：核心新药NMRA-861销售有望达12亿美元 上调Neumora(NMRA.US)目标价至5美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2553426987","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553426987?lang=zh_cn&edition=full","pubTime":"2025-07-21 14:35","pubTimestamp":1753079726,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，瑞穗分析师Graig Suvannavejh发表研报，将Neumora Therapeutics目标价从4美元上调至5美元，并维持“跑赢大盘”评级。此次评级调整源于Neumora在7月9日宣布启动NMRA-861的一期临床试验。NMRA-861是一种高效、选择性正向变构调节剂，该公司正开发其用于治疗精神分裂症及其他神经精神类疾病。瑞穗预测，该药物有望于2034年在美国上市，经风险调整前测算，NMRA-861在2037年的销售额或将达到12亿美元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1319975.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"瑞穗：核心新药NMRA-861销售有望达12亿美元 上调Neumora(NMRA.US)目标价至5美元","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["NMRA"],"gpt_icon":0},{"id":"2518276710","title":"Neumora Therapeutics, Inc.盘中异动 早盘股价大跌5.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518276710","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518276710?lang=zh_cn&edition=full","pubTime":"2025-03-10 22:55","pubTimestamp":1741618521,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日22时55分，Neumora Therapeutics, Inc.股票出现异动，股价大幅下跌5.37%。Neumora Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.27%。Neumora Therapeutics, Inc.公司简介：Neumora Therapeutics Inc 是一家临床阶段的生物制药公司，其成立的目的是通过采取一种完全不同的方法来开发脑部疾病的治疗方法，以应对全球脑部疾病危机。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031022552198a2b17c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031022552198a2b17c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","NMRA","BK4007","BK4139"],"gpt_icon":0},{"id":"2518210334","title":"Neumora Therapeutics, Inc.2024财年实现净利润-2.44亿美元，同比减少3.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518210334","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518210334?lang=zh_cn&edition=full","pubTime":"2025-03-09 00:01","pubTimestamp":1741449669,"startTime":"0","endTime":"0","summary":"3月9日，Neumora Therapeutics, Inc.公布财报，公告显示公司2024财年净利润为-2.44亿美元，同比减少3.39%；其中营业收入为0.00美元，每股基本收益为-1.53美元。从资产负债表来看，Neumora Therapeutics, Inc.总负债29.91百万美元，其中短期债务1.85百万美元，资产负债比为0.11，流动比率为0.11。机构评级：截至2025年3月9日，当前有6家机构对Neumora Therapeutics, Inc.目标价做出预测，其中目标均价为6.67美元，其中最低目标价为2.00美元，最高目标价为18.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250309000231a266b3dc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250309000231a266b3dc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","NMRA"],"gpt_icon":0},{"id":"2517727458","title":"Stifel：下调Neumora Therapeutics(NMRA.US)评级，由买入调整至持有评级, 目标价由6.00美元调整至2.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2517727458","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517727458?lang=zh_cn&edition=full","pubTime":"2025-03-08 00:44","pubTimestamp":1741365844,"startTime":"0","endTime":"0","summary":"Stifel：下调Neumora Therapeutics(NMRA.US)评级，由买入调整至持有评级, 目标价由6.00美元调整至2.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/08004448604766.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LENZ","NMRA"],"gpt_icon":0},{"id":"2516162054","title":"HC Wainwright & Co.：维持Neumora Therapeutics(NMRA.US)评级，由买入调整至买入评级, 目标价由30.00美元调整至18.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2516162054","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516162054?lang=zh_cn&edition=full","pubTime":"2025-03-04 19:55","pubTimestamp":1741089323,"startTime":"0","endTime":"0","summary":"HC Wainwright & Co.：维持Neumora Therapeutics(NMRA.US)评级，由买入调整至买入评级, 目标价由30.00美元调整至18.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/04195548519788.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["NMRA","LENZ"],"gpt_icon":0},{"id":"1177838069","title":"Neumora Therapeutics 2024年第四季度GAAP每股收益$(0.37)，优于预期的$(0.45)，现金余额为3.076亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1177838069","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177838069?lang=zh_cn&edition=full","pubTime":"2025-03-03 20:18","pubTimestamp":1741004329,"startTime":"0","endTime":"0","summary":"Neumora Therapeutics(LENZ) 2024年第四季度GAAP每股收益$(0.37)，优于预期的$(0.45)，现金余额为3.076亿美元以上内容来自Benzinga Earnings专栏，原文如下：Neumora $Therapeutics(LENZ)$ Q4 2024 GAAP EPS $(0.37) Beats $(0.45) Estimate, Cash Balance Of $307.6M","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","NMRA"],"gpt_icon":0},{"id":"2512859654","title":"Neumora Therapeutics, Inc.盘中异动 早盘股价大跌5.20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2512859654","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512859654?lang=zh_cn&edition=full","pubTime":"2025-02-19 22:56","pubTimestamp":1739976980,"startTime":"0","endTime":"0","summary":"北京时间2025年02月19日22时56分，Neumora Therapeutics, Inc.股票出现异动，股价大幅下跌5.20%。Neumora Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.50%。Neumora Therapeutics, Inc.公司简介：Neumora Therapeutics Inc 是一家临床阶段的生物制药公司，其成立的目的是通过采取一种完全不同的方法来开发脑部疾病的治疗方法，以应对全球脑部疾病危机。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219225620a24bffeb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219225620a24bffeb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","NMRA","BK4139","LENZ"],"gpt_icon":0},{"id":"2511213325","title":"Neumora Therapeutics, Inc.盘中异动 早盘快速下跌5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2511213325","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2511213325?lang=zh_cn&edition=full","pubTime":"2025-02-13 23:23","pubTimestamp":1739460231,"startTime":"0","endTime":"0","summary":"北京时间2025年02月13日23时23分，Neumora Therapeutics, Inc.股票出现波动，股价快速跳水5.00%。Neumora Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.26%。Neumora Therapeutics, Inc.公司简介：Neumora Therapeutics Inc 是一家临床阶段的生物制药公司，其成立的目的是通过采取一种完全不同的方法来开发脑部疾病的治疗方法，以应对全球脑部疾病危机。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250213232351a244b6ab&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250213232351a244b6ab&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NMRA","BK4139","BK4007","LENZ"],"gpt_icon":0},{"id":"2509493522","title":"Neumora Therapeutics, Inc.盘中异动 下午盘快速上涨5.11%报1.96美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2509493522","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509493522?lang=zh_cn&edition=full","pubTime":"2025-02-05 03:05","pubTimestamp":1738695957,"startTime":"0","endTime":"0","summary":"北京时间2025年02月05日03时05分，Neumora Therapeutics, Inc.股票出现异动，股价急速拉升5.11%。Neumora Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为1.38%。Neumora Therapeutics, Inc.公司简介：Neumora Therapeutics Inc 是一家临床阶段的生物制药公司，其成立的目的是通过采取一种完全不同的方法来开发脑部疾病的治疗方法，以应对全球脑部疾病危机。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250205030557961801c1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250205030557961801c1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","NMRA","LENZ","BK4139"],"gpt_icon":0},{"id":"2508144364","title":"Neumora Therapeutics, Inc.盘中异动 股价大跌5.15%报1.83美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2508144364","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2508144364?lang=zh_cn&edition=full","pubTime":"2025-02-03 23:03","pubTimestamp":1738594983,"startTime":"0","endTime":"0","summary":"北京时间2025年02月03日23时03分，Neumora Therapeutics, Inc.股票出现波动，股价急速下跌5.15%。Neumora Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.74%。Neumora Therapeutics, Inc.公司简介：Neumora Therapeutics Inc 是一家临床阶段的生物制药公司，其成立的目的是通过采取一种完全不同的方法来开发脑部疾病的治疗方法，以应对全球脑部疾病危机。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250203230303abc10e72&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250203230303abc10e72&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4007","LENZ","NMRA"],"gpt_icon":0},{"id":"2505179270","title":"Neumora Therapeutics, Inc.盘中异动 股价大跌5.29%报1.97美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2505179270","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2505179270?lang=zh_cn&edition=full","pubTime":"2025-01-23 23:27","pubTimestamp":1737646057,"startTime":"0","endTime":"0","summary":"北京时间2025年01月23日23时27分，Neumora Therapeutics, Inc.股票出现波动，股价大幅跳水5.29%。Neumora Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.25%。Neumora Therapeutics, Inc.公司简介：Neumora Therapeutics Inc 是一家临床阶段的生物制药公司，其成立的目的是通过采取一种完全不同的方法来开发脑部疾病的治疗方法，以应对全球脑部疾病危机。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250123232738960e5015&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250123232738960e5015&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","BK4007","NMRA"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.neumoratx.com","stockEarnings":[{"period":"1week","weight":0.0653},{"period":"1month","weight":-0.0742},{"period":"3month","weight":-0.1719},{"period":"6month","weight":0.4521},{"period":"1year","weight":0.0872},{"period":"ytd","weight":0.1844}],"compareEarnings":[{"period":"1week","weight":-0.002},{"period":"1month","weight":0.0015},{"period":"3month","weight":0.0293},{"period":"6month","weight":0.0839},{"period":"1year","weight":0.139},{"period":"ytd","weight":0.0128}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Neumora Therapeutics, Inc.成立于2019年11月，当时是一家特拉华州公司，名称为RBNC Therapeutics, Inc.。该公司于2021年10月更名为Neumora Therapeutics, Inc.。该公司是一家临床阶段的生物制药公司，旨在应对全球脑部疾病危机，对脑部疾病的治疗方法采取一种根本不同的方法。该公司的治疗管道规模迅速扩大，目前包括七个临床和临床前神经科学项目，针对广泛的未得到充分服务的神经精神疾病和神经退行性疾病的新的作用机制。该公司最先进的候选产品navacaprant（NMRA-140）是一种新型的每日一次口服kappa阿片受体（KOR）拮抗剂，正在开发用于治疗重度抑郁症（MDD），该公司认为，如果获得批准，这种药物有可能提供相对于标准护理的显著优势。","exchange":"NASDAQ","name":"Neumora Therapeutics, Inc.","nameEN":"Neumora Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Neumora Therapeutics, Inc.(NMRA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Neumora Therapeutics, Inc.(NMRA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Neumora Therapeutics, Inc.,NMRA,Neumora Therapeutics, Inc.股票,Neumora Therapeutics, Inc.股票老虎,Neumora Therapeutics, Inc.股票老虎国际,Neumora Therapeutics, Inc.行情,Neumora Therapeutics, Inc.股票行情,Neumora Therapeutics, Inc.股价,Neumora Therapeutics, Inc.股市,Neumora Therapeutics, Inc.股票价格,Neumora Therapeutics, Inc.股票交易,Neumora Therapeutics, Inc.股票购买,Neumora Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Neumora Therapeutics, Inc.(NMRA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Neumora Therapeutics, Inc.(NMRA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}